Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Everolimus|DRUG: Bevacizumab|DRUG: Paclitaxel|DRUG: Placebo|DRUG: Bevacizumab|DRUG: Paclitaxel
Sponsor: SCRI Development Innovations, LLC
Collaborators: Novartis